Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study will examine the effectiveness of low-dose peginterferon and ribavirin therapy for
certain patients with chronic hepatitis C-a liver disease that, in some patients, can
progress to cirrhosis of the liver, liver cancer, and liver failure.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)